ISSUE 1471
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Bellafill (Suneva), a dermal filler approved earlier for correction of nasolabial folds, has now also been approved by the FDA for correction of moderate to severe, atrophic, distensible facial acne scars on the cheek in adults ≥21 years old. It is the only dermal filler approved in the US for correction of facial acne scars.
MECHANISM OF ACTION — Bellafill contains 80% bovine collagen solution (including 0.3% lidocaine) and 20% non-resorbable polymethylmethacrylate (PMMA) microspheres. The collagen adds volume below pitted acne scars to lift them to the level of the surrounding skin, while the PMMA microspheres, according to the manufacturer, create a matrix that supports endogenous collagen production and provides long-term structural support.
A CLINICAL STUDY — Approval of Bellafill for atrophic facial acne scars was based on a double-blind trial in 147 patients with
... more- J Karnik et al. A double-blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars. J Am Acad Dermatol 2014; 71:77.
- SM Daines and EF Williams. Complications associated with injectable soft-tissue fillers: a 5-year retrospective review. JAMA Facial Plast Surg 2013; 15:226.
- FDA. Unintentional injection of soft tissue filler into blood vessels in the face: FDA safety communication. Available at: http://www.fda.gov. Accessed June 11, 2015.
- Cost according to the manufacturer.

Would you like to read the rest of this article? Gain access below.
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Article code: 1471d
Electronic, downloadable article - $45